|
| Status |
Public on Oct 06, 2015 |
| Title |
sample_01-TT-001 [copy number] |
| Sample type |
genomic |
| |
|
| Source name |
Breast cancer, CHER-LOB Arm C, pre-treated
|
| Organism |
Homo sapiens |
| Characteristics |
disease state: HER2-positive breast cancer
tissue: breast cancer
cher-lob arm: C
arm description: chemotherapy+trastuzumab+lapatinib
pcr (1=yes): 0
|
| Treatment protocol |
CHER-LOB is a phase II, randomized, multicenter, trial in which 121 patients with primary HER2-positive breast cancer were randomized to receive preoperative chemotherapy with weekly paclitaxel times 12 followed by 4 courses of 3-weekly FEC (fluorouracil, epirubicin and cyclophosphamide) plus either trastuzumab (Arm A), lapatinib (Arm B) or the combination of trastuzumab and lapatinib (Arm C). The trial design, eligibility criteria, statistical analysis, and clinical results including response, surgery outcomes and treatment safety are described in details elsewhere.
|
| Growth protocol |
NA
|
| Extracted molecule |
genomic DNA |
| Extraction protocol |
Qiagen DNeasy Blood & Tissue Kit (manufacturer's protocol).
|
| Label |
Biotin
|
| Label protocol |
Affymetrix (manufacturer's protocol).
|
| |
|
| Hybridization protocol |
Affymetrix® Genome-Wide Human SNP Nsp/Sty 6.0 (manufacturer's protocol).
|
| Scan protocol |
Affymetrix GeneChip Scanner 3000 7G (manufacturer's protocol).
|
| Data processing |
Affymetrix® Genotyping Console.
|
| |
|
| Submission date |
Feb 27, 2015 |
| Last update date |
Oct 06, 2015 |
| Contact name |
Enrico Tagliafico |
| E-mail(s) |
enrico.tagliafico@unimore.it
|
| Organization name |
University of Modena and Reggio Emilia
|
| Department |
Center for Genome Research
|
| Street address |
Via Campi 287
|
| City |
Modena |
| State/province |
MO |
| ZIP/Postal code |
41126 |
| Country |
Italy |
| |
|
| Platform ID |
GPL6801 |
| Series (2) |
| GSE66398 |
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer [copy number] |
| GSE66399 |
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer |
|
